News

FDA to Review Nuplazid as Treatment for Dementia-related Psychosis

The U.S. Food and Drug Administration (FDA) will review Acadia Pharmaceutical’s application asking that Nuplazid (pimavanserin) also be approved to treat hallucinations and delusions associated with various forms of dementia-related psychosis, the company announced. The supplemental new drug application (sNDA) was granted standard review status, and the…

World Brain Day 2020 Dedicated to Parkinson’s Disease

The 6th annual World Brain Day, celebrated Wednesday (July 22), will be dedicated to raising awareness for Parkinson’s disease and promoting patient advocacy. The World Federation of Neurology (WFN) founded and coordinates the event to raise public awareness and promote advocacy related to brain health. This year, the…